explore -WSS

explore

author：explore 2025-08-06 04:47:32 - browse：7

NEW ORLEANS — For some patients suffering with certain blood cancers, CAR-T therapy can offer the tantalizing chance to end their disease with a single treatment.

But the immunotherapy takes time to manufacture, and patients often have to wait weeks to actually receive an infusion once they’re eligible. For some patients with especially aggressive cancer, they can die while waiting for the therapy to arrive.

That’s spurred CAR-T manufacturers to find ways to speed up manufacturing. The industry is testing newer — and possibly better — CAR-T cells that can be made more quickly. Researchers working with Novartis presented Phase 1 clinical trial data Sunday on a new CAR-T cell made with a rapid manufacturing process at the annual American Society of Hematology meeting.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Dramatically reducing cancer deaths requires the PASTEUR Act

focus

hotspot

WSS

Bristol 'take

Bristol 'take

The drug industry sees a key ally in the Senate prevail

Liquid biopsy for lung cancer is launched by Delfi

When women are denied an abortion, their children fare worse than peers

Why age limits for politicians are a terrible idea

knowledge

explore

hotspot

The cancer drug shortage isn’t new — and neither are the solutions

The drug industry sees a key ally in the Senate prevail

United colonoscopy coverage change 'may cost lives,' doctors say

Stroke deaths set to near 10 million globally by 2050

Jerome Adams on the need for new antivirals for Covid

A Q&A with the global head of Boehringer Ingelheim's innovation unit

DIEP, the 'gold standard' of breast reconstruction, is under threat

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

Heart attack and stroke risk calculators need revising

Why Charlie Gard's case is so disturbing to Americans

hotspot

FDA rejects Alnylam's heart disease treatment over insufficient data

Was Amgen transparent enough on FDA's concern on cancer drug?

A Q&A with the global head of Boehringer Ingelheim's innovation unit

My superpower is killing ticks

OTC birth control: A brief history of over the counter pill design

Who is Magistrate Judge Moxila Upadhyaya in Trump's Jan. 6 case?

focus

leisure time

hotspot

knowledge